Hepatocyte transplantation (HT) has emerged as a promising alternative to orthotopic liver transplantation, yet liver preconditioning is needed to promote hepatocyte engraftment. A method of temporary occlusion of the portal flow called reversible portal vein embolization (RPVE) has been demonstrated to be an efficient method of liver preconditioning. By providing an additional regenerative stimulus, repeated reversible portal vein embolization (RRPVE) could further boost liver engraftment. The aim of this study was to determine the efficiency of liver engraftment of transplanted hepatocytes after RPVE and RRPVE in a rat model. Green fluorescent protein-expressing hepatocytes were isolated from transgenic rats and transplanted into 3 groups of syngeneic recipient rats. HT was associated with RPVE in group 1, with RRPVE in group 2, and with sham embolization in the sham group. Liver engraftment was assessed at day 28 after HT on liver samples after immunostaining. Procedures were well tolerated in all groups. RRPVE resulted in increased engraftment rate in total liver parenchyma compared with RPVE (3.4% ± 0.81% versus 1.4% ± 0.34%; P < 0.001). In conclusion, RRPVE successfully enhanced hepatocyte engraftment after HT and could be helpful in the frame of failure of HT due to low cell engraftment.
glycogen storage disease type 1, (3) infantile Refsum's disease, (4) factor VII deficiency, (5) urea cycle disorders, (6, 7) and phenylketonuria. (8) However, disease correction has been incomplete and transient, and the need for liver transplantation has not been averted. (9) In a consensus meeting on clinical HT held in London in 2009, experts focused on the need for methods to increase repopulation of the liver with donor hepatocytes because HT into an unconditioned recipient liver results only in low rates of cell engraftment. (10) Indeed, spontaneous hepatocyte engraftment following HT is limited, estimated to represent <1% of total liver mass. (11) In order to obtain clinical improvement of metabolic disorders, a 5%-10% engraftment rate is thought to assure a sufficient quantity of the missing enzyme or protein. (12) In small animal models, the general concept of HT has been the infusion of hepatocytes from syngeneic donors into recipients through intrasplenic or portal
Original article | 99 vein injection. Efficient engraftment is limited because the transplanted hepatocytes become entrapped in portal spaces and are subsequently destroyed by the recipient's immune system. (13, 14) A significant engraftment occurs only if the resident hepatocytes are destroyed or blocked, developing the concept of liver preconditioning. (15) Most of the protocols developed to promote cell engraftment have been based on the use of toxins (16, 17) or invasive methods such as hepatic irradiation (18) or partial hepatectomy. (19) These methods have been successful in increasing cell engraftment to sufficient quantities to produce a biological effect. However, these procedures used in small animal models cannot be transferred in clinical practice, and alternative strategies are needed.
Among methods proposed to promote cell engraftment, partial occlusion of portal blood flow was thought to be interesting to develop in a minimally invasive setting. Occlusion of 1 branch of the portal vein results in hemodynamic changes and up-regulation of humoral mediators, (20) leading to atrophy of ipsilateral segments and hypertrophy of contralateral segments. This partial portal vein occlusion is routinely achieved in clinical practice by partial portal vein embolization (PVE) to induce hypertrophy of the future remnant liver after hepatectomy and, consequently, to increase the number of cancer patients amenable to surgery. (21) A nonabsorbable material is commonly used for embolization because it provides effective and permanent vascular occlusion. Longterm effects are not considered because the embolized liver is generally removed. PVE has been shown to induce hepatocyte proliferation and liver regeneration in rodents (22) and swine. (23) Initially, our team applied PVE as liver preconditioning before HT and demonstrated increased cell engraftment in nonhuman primates (24) and biological effects in rabbits. (25, 26) Yet, unlike surgical practice, the embolized segments are not meant to be removed in the setting of HT; hence, we focused on developing a minimally invasive method for liver preconditioning that would be both safe and routinely applicable. A method of temporary occlusion of the portal vein with an absorbable material (a biological glue) was established. In nonhuman primates, this method called reversible portal vein embolization (RPVE) was shown to stimulate hepatocyte proliferation and liver regeneration. (27) Complete recanalization occurred within 2 weeks, avoiding longterm liver scarring. Subsequently, liver preconditioning using RPVE demonstrated efficient repopulation of the liver with transplanted autologous hepatocytes in nonhuman primates. (28) These results led the authors to consider the possibility of repeated reversible portal vein embolization (RRPVE) to further boost liver repopulation. Because RPVE induces a temporary occlusion, it can allow a rapid second embolization at the moment of completion of the portal recanalization, providing an additional regenerative stimulus. In a recent study in rats, (29) the authors showed that RRPVE induced additional hepatocyte proliferation and an increase in liver weight and volume when compared with single RPVE. RRPVE was well tolerated, and histological analysis showed no cell necrosis and limited apoptosis. This repeated stimulus could promote liver engraftment after HT, improving repopulation of the liver by transplanted hepatocytes. The purpose of this study was to determine the efficiency of RPVE and RRPVE to promote liver engraftment of transplanted hepatocytes in a rat model.
Materials and Methods

aniMals
Rats were housed in the animal facility of INSERM UMS 33, Villejuif, France, in filter-topped cages (2 per cage) under clean, nonsterile, standard conditions for at least 5 days before the experiment. Animals were checked daily, fed with standard laboratory chow, and given free access to water. Procedures were approved by the French Ministry of Higher Education and Research (number 02008.02). All animals were treated in accordance with the European Community laws for animal care. Male Sprague-Dawley green fluorescent protein (GFP)-expressing transgenic rats were used as hepatocyte donors, kindly obtained from the animal facility of INSERM 1064, Nantes, France. (30) Recipient rats were male Sprague-Dawley (Janvier Labs, St Bertevin, France), weighing 250-350 g, aged 8-10 weeks old, and having a syngeneic background to the donor rats. General anesthesia during animal procedures was provided using isoflurane/oxygen (Iso-Vet, Piramal Healthcare, Northumberland, United Kingdom) supplied by a vaporizer at a concentration of 3% for induction and 2% for maintenance. Buprenorphin (Buprécare, Axience, Pantin, France) at the concentration of 0.1 mg/kg body weight was applied intracutaneously during anesthesia for postoperative analgesia. Study endpoints were defined to avoid unnecessary suffering of the animals.
HepatOcYte isOlatiOn
GFP-expressing hepatocytes were isolated employing 2-step in situ collagenase perfusion of the liver (Worthington, Lakewood, NJ), as previously described (31) (Fig. 1A) , and then purified from nonparenchymal cells 
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by sedimentation on Percoll isodensity solution (GE Healthcare, Uppsala, Sweden). Freshly isolated hepatocytes (Fig. 1B) were resuspended at 1 × 10 7 cells/mL in Dulbecco's modified Eagle's medium (Gibco Life Technologies, Foster City, CA) containing fetal bovine serum, bovine serum albumin, glutamine, and antibiotics. Hepatocyte viability was determined by trypan blue dye exclusion and was maintained at >90% through the experiments. A total of 10 GFP-expressing transgenic rats were killed for hepatocyte isolation.
liver precOnditiOning Using rpve
Surgery was performed as previously described. (31) Briefly, procedures were performed through a subcostal laparotomy. Selective catheterization of the portal branch for the left lateral lobe (LLL) and median lobe (ML) was performed by direct puncture of the corresponding branch with a 27-gauge needle (Microflex, Vygon, Écouen, France; Fig. 1C ). The portal branch for the LLL and ML was occluded progressively with the powdered form of an absorbable gelatin sponge (GelitaSpon, Gelita Medical, Eberbach, Germany), performing a selective RPVE of 70% of portal vein flow. The right and caudate portal branches were left patent. Gelatin powder was suspended in saline solution (0.07 g/mL), and the mixture was homogenized in a 37°C water bath. A volume of 0.3 mL of the mixture was used for the embolization. Hemostasis of the injection point was achieved by light compression with a sterile compress.
HepatOcYte transplantatiOn
HT was performed immediately after RPVE. After splenic mobilization, GFP-expressing hepatocytes, freshly isolated from the liver of syngeneic donor rat, were transplanted through splenic injection (Fig. 1D) . A volume of 2 mL of a suspension containing 2 × 10 7 hepatocytes was slowly injected through a 29-gauge needle. Hemostasis was achieved by light pressure over the puncture site. A 4/0 polyglactin (Vicryl, Ethicon, Issy-les-Moulineaux, France) double-layer running suture was used for abdominal closure.
repeated stiMUlUs Using rrpve
Procedures were performed through an iterative subcostal laparotomy. After cautious adhesiolysis, access was made to the hepatic pedicle. RRPVE was performed as a RPVE procedure. A time frame of 14 days between the RPVE + HT procedure and RRPVE was adopted from previous experiments. (29) liver saMple cOllectiOn Recipient rats were killed by exsanguination under general anesthesia, and 2 tissue samples were collected from each of the 4 liver lobes and from the spleen. The samples were rapidly embedded in an optimal cutting temperature compound (Tissue-Tek, Sakura, Villeneuve d'Ascq, France), frozen in liquid nitrogen, and then stored at -80°C. Nine frozen sections (5-mm thickness) of each sample were prepared for each rat.
detectiOn OF transplanted HepatOcYtes
Immunostaining was carried out by incubation of cryostat sections with a mouse monoclonal antibody against GFP (dilution 1:100; Living Colors, Clontech, Mountain View, CA) overnight at 4°C. Binding of the primary antibody was detected after incubation with a secondary sheep anti-mouse polyclonal antibody linked to horseradish peroxidase (dilution 1:100; GE Healthcare, Little Chalfont, United Kingdom) for 1 hour at room temperature. Finally, the peroxidase reaction was carried out with diaminobenzidine (Dako, Carpinteria, CA). For specific detection of transplanted hepatocytes within splenic parenchyma, immunostaining was carried out with primary mouse monoclonal antibody against albumin (dilution 1:100; Cedarlane, Burlington, Ontario, Canada). All immunostains were counterstained with hematoxylin-eosin, dehydrated, cover-slipped, and examined under a light microscope (20× magnification).
tissUe analYsis
The engraftment ratios of the transplanted hepatocytes in the recipient liver were determined by counting the number of GFP+ cells and expressed as the percentage of GFP+ cells per total number of hepatocytes (approximately 24,000 cells from 30 random areas from the 4 liver lobes for each rat). The ratio of GFP+ hepatocytes in a specific area was also obtained. The sites of engrafted hepatocytes were defined as liver zone 1 (periportal area), zone 2 (intermediate area), or zone 3 (centrilobular area).
BiOcHeMical analYsis OF rat serUM
Blood samples were collected through the tail vein under general anesthesia before operation and at days 3, 7, 14, 17, 21, and 28 after transplantation, and they were immediately centrifuged at 2000g for 6 minutes. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total bilirubin levels were measured in the local biochemistry department.
eXperiMental design
The studies were undertaken in 2 parts.
Short-term Study of the Distribution of Transplanted Hepatocytes
The first experiment was designed to establish in the short term the engraftment of the infused hepatocytes within the recipient liver. GFP-expressing hepatocytes were transplanted after RPVE into Sprague-Dawley rats (n = 15). Recipient rats were killed at days 5, 10, and 28 after the procedure. Transplanted hepatocytes were detected on liver samples after immunostaining.
Assessment of RRPVE Impact on Hepatocyte Engraftment
In the second part, 3 experimental groups were used (Fig. 2) . In group 1, recipients (n = 18) were submitted to liver preconditioning using RPVE before HT during the same procedure. In group 2, recipients (n = 14) were submitted to this same procedure, followed by a second RPVE 14 days later. In the sham group, recipients (n = 5) were submitted to intraportal injection of 0.3 mL of saline before HT. All recipient rats were sacrificed for sample collection 28 days after the HT procedure.
statistical MetHOds
A power calculation was performed in order to limit the number of animals. The Mann-Whitney U test was used to investigate that hepatocyte engraftment in group 2 (experimental) was 30% superior than in group 1. Type I and II error rates were set at 0.05 and 0.1, respectively. Considering a 25% mortality rate, a group size of 13 animals was determined.
Continuous variables are presented as mean ± standard deviation (SD). Categorical variables are presented as percentage values and analyzed using a chi-square test. P ≤ 0.05 was considered statistically significant. Statistical analysis was performed using GraphPad Prism 4 software (San Diego, CA).
Results
HepatOcYte isOlatiOn
The livers of 10 GFP-expressing transgenic donor rats were perfused with collagenase, and 8 livers were selected for the HT procedure. In 2 cases, incorrect catheterization of the inferior vena cava led to insufficient perfusion, and the liver was discarded. Isolation provided a median count of 3 × 10 9 (1.9-5.6 × 10 9 ) cells, depending mainly on the liver volume. After Percoll purification, 15%-38% of submitted cells were gathered. Young donor rats gave the best yield. Hepatocyte viability averaged 90% in all cases. Sustained expression of nuclear GFP was observed in isolated hepatocytes during fluorescence microscopy analysis.
tOlerance OF tHe prOcedUres
Mortality and Morbidity
In a preliminary study, selective RPVE was developed in the rat using a volume of 0.5 mL of the absorbable agent. (29) The first 2 rats submitted to RPVE and HT presented immediate portal vein thrombosis and death. Consequently, RPVE was performed using 0.3 mL of the absorbable agent, and no further portal vein thrombosis was observed. Two additional deaths occurred in group 1: 1 rat died during anesthesia and 1 from an unexplained cause. Two rats died in group 2 due to bleeding or small bowel injury during adhesiolysis. All rats survived in the sham group. One rat in group 2 was reoperated on 2 hours after the procedure due to evisceration and survived.
Biochemical Analysis
Acute transient injury was detected by elevated ALT and AST levels on day 3 (≈2-fold), which was less important in the sham group (Fig. 3A,B) . The ALT and AST values returned to normal by day 7 in all the Original article | 103 groups. RRPVE induced moderate transient injury 3 days after the procedure, and ALT and AST values returned to normal 7 days after the procedure. ALP levels declined transiently after each embolization procedure (Fig. 3C ), but no impairment of liver function, represented by the total bilirubin level, was observed in any of the groups (Fig. 3D) .
Histological Analysis
At day 5 after transplantation, histological analysis of embolized lobes did not reveal any cell necrosis (Fig. 3E) or signs of hepatic cellular inflammation. The absorbable embolization material was observed in distal portal branches at day 5 ( Fig. 3F) and was absent at day 10 (not shown). Sinusoidal dilatations were observed in the nonembolized lobes at day 5 (Fig. 4A) . Liver histology in the nonembolized lobes returned to normal at day 10 ( Fig. 4B) .
sHOrt-terM distriBUtiOn OF transplanted HepatOcYtes
Total mean engraftment ratio in the nonembolized lobes was 0.77% ± 0.43% at day 5, 0.91% ± 0.08% at day 10, and 1.28% ± 0.51% at day 28. At day 5, histological examination of the nonembolized lobes revealed that the donor hepatocytes Fig. 2 . Study protocol. Time frame of experimental groups and diagram of the rat liver during the experimental protocol, showing RPVE of the portal branches for ML and LLL of the rat liver, the portal branches for RL and CL remaining patent, before immediate HT in group 1. The same procedure is followed by a RRPVE 14 days later in group 2.
were predominantly distributed in the periportal area, as mean engraftment ratios were 1.6% ± 1.29%, 0.22% ± 0.16%, and 0.12% ± 0.12% in the periportal, intermediate, and centrilobular areas, respectively (Fig. 4A) . At day 10, mean engraftment ratios were 1.5% ± 0.04%, 0.61% ± 0.04%, and 0.32% ± 0.13% in the periportal, intermediate, and centrilobular areas, respectively (Fig. 4B) . At day 28, transplanted liver transplantatiOn, vol. 25, no. 1, 2019 gaillard et al.
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hepatocytes were evenly distributed within the parenchyma, and mean engraftment ratios were 1.5% ± 0.69%, 1.2% ± 0.43%, and 1.1% ± 0.38% in the periportal, intermediate, and centrilobular areas, respectively (Fig. 4C) . Figure 4D shows a marked difference in the zonal distribution of transplanted hepatocytes at days 5, 10, and 28 after RPVE and transplantation procedure. 
assessMent OF rrpve iMpact On HepatOcYte engraFtMent
Mean engraftment ratio of the GFP-expressing transplanted hepatocytes in the total liver parenchyma increased significantly in group 2 compared with group 1 (3.4% ± 0.81% [n = 16] versus 1.4% ± 0.34% [n = 12]; P < 0.001) at day 28. The engraftment ratio in total liver parenchyma was significantly higher in group 1 (1.4% ± 0.34%, n = 16 versus 0.49% ± 0.13%; n = 5; P < 0.001) and in group 2 (3.4% ± 0.81%, n = 12 versus 0.49% ± 0.13%; n = 5; P < 0.001) than in the sham group. In the sham group, GFP-expressing transplanted hepatocytes were evenly distributed in nonembolized and embolized lobes at day 28 (Fig. 5A) . In groups 1 and 2, GFP-expressing hepatocytes were observed mostly in nonembolized lobes at day 28 ( Fig. 5B,C) . Figure 5D shows mean engraftment ratios in the experimental groups. The results are summarized in Table 1 .
detectiOn OF transplanted HepatOcYtes in tHe splenic parencHYMa
Numerous GFP-expressing cells were observed within the splenic parenchyma at days 10 ( Fig. 6A) and 28  (Fig. 6B ) after intrasplenic injection of the suspension containing the GFP-expressing hepatocytes. No cell count was performed due to the high number of cells and the heterogeneity of distribution in the splenic parenchyma. In order to confirm that the GFPexpressing cells were the GFP-expressing transplanted hepatocytes, serial sectioning was performed on splenic samples, followed by immunostaining with antibody against GFP and antibody against rat albumin (Fig. liver transplantatiOn, vol. 25, no. 1, 2019 gaillard et al.
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Discussion
Because HT into an unconditioned recipient liver results in low rates of cell engraftment, clinically Group 1 (n = 18) 2.5% ± 0.63% 0.19% ± 0.03% 1.4% ± 0.34% <0.001 Group 2 (n = 14)
5.3% ± 1.5% 1.4% ± 0.37% 3.4% ± 0.81% <0.001
NOTE: Data are given as means ± SD. *Chi-square test. applicable methods of liver preconditioning have been developed. In the consensus on clinical HT held in 2009, hepatic irradiation, hepatic resection, and portal embolization have been advocated. (10) PVE is regarded as a safe and accepted technique in surgical practice. It is considered a minimally invasive procedure because access to the portal branch is performed using a percutaneous transhepatic approach after a puncture technique with ultrasonic guidance under local anesthesia. (32) The precise biological and cellular mechanisms of liver regeneration following portal embolization remain unclear, involving many molecular pathways, such as tumor necrosis factor alpha and interleukins 6 and 1. (20) The underlying mechanisms of PVE in liver preconditioning before HT are also open questions. It is thought that endothelial damage allows transplanted cells to enter liver parenchyma, (14) whereas the release of inflammatory mediators facilitates parenchymal remodeling during cell engraftment. (33) In an effort to develop a less invasive approach for liver preconditioning, our team focused on a temporary PVE, ie, RPVE. This method was proven to be safe and induced hypertrophy of the nonembolized liver segments in a nonhuman primate model (27) and was applied successfully in a preliminary study in humans before liver surgery. (34) Consequently, RPVE was used as liver preconditioning to enhance engraftment of autologous hepatocytes in nonhuman primates, and the regenerative response induced by the RPVE significantly increased hepatocyte engraftment, reaching 7.4% in the nonembolized lobe. (28) Because RPVE induces a temporary occlusion, the possibility to proceed to a second embolization at the moment of completion of portal recanalization was considered to provide an additional regenerative stimulus. In a rat model, RRPVE induced additional hepatocyte proliferation and an increase in liver weight and volume compared with RPVE. (29) In the present study, RRPVE was applied to promote further liver engraftment. Because the transplanted hepatocytes have no selective advantage in comparison with the resident cells, both should proliferate in response to the RRPVE stimulus in the nonembolized lobes, and the engraftment rate in these lobes should not differ. However, the repetition of the RPVE should lead to atrophy of the embolized lobes, increasing the number of the transplanted hepatocytes within the total liver mass. In a previous study in rats, complete recanalization of portal branches was observed at day 14 on repeated portograms. (29) Thus, the time lapse between the first procedure and the RRPVE was decided to be 14 days. Because >90% of liver regeneration occurs within 7 days following partial portal occlusion in rats, (22) we did not expect any additional impact of the proliferation stimulus with a longer time interval.
In the preliminary experiments of this study, the aim was to assess the evolution of transplanted GFPexpressing hepatocytes in the host liver. Even though the hepatocyte donor rats had a syngeneic background to donor rats, the expression of GFP could induce an immunological reaction and decrease the survival of transplanted hepatocytes. Recipient rats were killed at days 5, 10, and 28 after the RPVE and HT procedure. At day 5, transplanted hepatocytes were predominantly distributed in the periportal area. Subsequently, distribution of the transplanted hepatocytes tends toward a homogenization within the hepatic lobule. More importantly, the transplanted hepatocytes were still visible at day 28, which was chosen for evaluation of hepatocyte engraftment in the present study. Interestingly, Maeda et al. recently published results regarding the fate of GFP-expressing hepatocytes transplanted in the liver of syngeneic wild-type rats after retrorsine administration. (35) Transplanted hepatocytes were still visible at day 28, but the authors demonstrated the disappearance of GFP-expressing hepatocytes at day 42, most likely involving an immunological reaction against GFP.
Procedures were well tolerated in all groups. Two rats in group 2 died because of difficulties accessing the portal pedicle because adhesiolysis is technically demanding in small animals. However, problems related to any relaparotomy should be ruled out because PVE is routinely performed by a transhepatic approach without laparotomy in humans. The results of histological analysis showed that embolization did not result in the necrosis of embolized lobes, inducing only sinusoidal dilatations in the nonembolized lobes. Liver histology returned to normal at day 10. Serum analysis showed a transient increase in aminotransferase levels without impairment of liver function.
In this study, we demonstrated that the repetition of RPVE at 14 days significantly improved hepatocyte engraftment after HT associated with RPVE. This increase was mainly due to improvement of hepatocyte engraftment in nonembolized lobes (5.3% ± 1.5% in group 2 versus 2.5% ± 0.63% in group 1; P < 0.001). Surprisingly, hepatocyte engraftment increased also in embolized lobes (1.4% ± 0.37% in group 2 versus 0.19% ± 0.03% in group 1; P < 0.001). This could be
Original article | 109 explained by difficulties of iterative access to the portal pedicle to perform RRPVE that could lead to a suboptimal embolization in some rats. Another hypothesis could be the persistence of transplanted hepatocytes in the splenic pulp that could continue to migrate through the portal vein into liver sinusoids and parenchyma. Longterm correction of the metabolic disorder in an animal model of liver-based metabolic deficiency using HT should be the next step of our approach. In future studies, our aim will be to apply liver preconditioning using RRPVE prior to HT in jaundiced Gunn rats, (36) an animal model of Crigler-Najjar syndrome type 1, which is caused by inherited bilirubin-uridine diphosphate glucuronosyltransferase 1 family, polypeptide A1 deficiency.
Previous studies have demonstrated that liver preconditioning using RPVE before HT improved hepatocyte engraftment, up to 7.4% in nonembolized lobes in the nonhuman primate model, (28) exceeding the 5% engraftment rate commonly thought to be necessary to obtain clinical improvement. However, a sufficient engraftment rate does not guarantee disease correction because in clinical studies, the function of transplanted cells has been short-lived, mainly because of the inability to treat or diagnose rejection. A general caveat of transplantation of allogenic hepatocytes is that it cannot be repeated. Recent progress in the field of regenerative medicine has set its focus on hepatocyte-like cells, generated from induced pluripotent stem cells, (37) that could allow iterative HT. Although fully mature hepatocyte-like cells have not yet been produced, it has been shown that they successfully engraft and pursue their maturation in situ. (38) However, safety studies have to be conducted before clinical use of such cells, and to date, the ideal cell type for hepatic regenerative medicine remains the primary hepatocyte. Yet, unlike transplantation of allogenic hepatocytes, RPVE can be repeated, taking advantage of the capacity of hepatocytes to proliferate if a mitotic stimulus is present. Portal embolization is safely and routinely performed in humans through a transhepatic approach, excluding the drawbacks of iterative laparotomy in the small animal model. Thus, RRPVE could be helpful in the frame of failure of HT due to low cell engraftment.
